Citius Pharmaceuticals 過去の業績

過去基準チェック /06

Citius Pharmaceuticalsの収益は年間平均-12.4%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間10.3% 109.2%割合で増加しています。

主要情報

-12.39%

収益成長率

12.49%

EPS成長率

Pharmaceuticals 業界の成長	5.95%
収益成長率	109.17%
株主資本利益率	-41.57%
ネット・マージン	-909.87%
前回の決算情報	31 Dec 2025

Recent updates

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Apr 06

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Dec 08

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Aug 01

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Apr 12

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Dec 25

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Sep 28

Citius Pharmaceuticals GAAP EPS of -$0.06

Aug 11

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

Aug 05

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Jul 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Dec 04

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Sep 26

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

Aug 28

収支内訳

Citius Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:CTXR 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 25	4	-36	31	9
30 Sep 25	0	-37	29	9
30 Jun 25	0	-41	31	10
31 Mar 25	0	-43	31	12
31 Dec 24	0	-41	31	11
30 Sep 24	0	-40	30	12
30 Jun 24	0	-40	29	12
31 Mar 24	0	-37	26	13
31 Dec 23	0	-39	25	14
30 Sep 23	0	-34	22	15
30 Jun 23	0	-31	18	16
31 Mar 23	0	-31	17	17
31 Dec 22	0	-28	16	16
30 Sep 22	0	-34	16	18
30 Jun 22	0	-31	15	16
31 Mar 22	0	-29	15	13
31 Dec 21	0	-26	13	12
30 Sep 21	0	-25	11	12
30 Jun 21	0	-24	11	11
31 Mar 21	0	-21	9	12
31 Dec 20	0	-21	9	12
30 Sep 20	0	-18	9	9
30 Jun 20	0	-17	8	9
31 Mar 20	0	-17	8	9
31 Dec 19	0	-16	7	9
30 Sep 19	0	-16	7	9
30 Jun 19	0	-15	7	8
31 Mar 19	0	-12	7	6
31 Dec 18	0	-13	6	8
30 Sep 18	0	-13	7	7
30 Jun 18	0	-13	7	5
31 Mar 18	0	-13	8	5
31 Dec 17	0	-11	8	2
30 Sep 17	0	-10	7	3
30 Jun 17	0	-10	7	4
31 Mar 17	0	-11	6	5
31 Dec 16	0	-9	5	4
30 Sep 16	0	-8	5	3
30 Jun 16	0	-7	3	2
31 Mar 16	0	-4	2	2
31 Dec 15	0	-3	1	2
30 Sep 15	0	-3	1	2

質の高い収益: CTXRは現在利益が出ていません。

利益率の向上: CTXRは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CTXRは利益が出ておらず、過去 5 年間で損失は年間12.4%の割合で増加しています。

成長の加速: CTXRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CTXRは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.2% ) と比較することは困難です。

株主資本利益率

高いROE: CTXRは現在利益が出ていないため、自己資本利益率 ( -41.57% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/01 01:59
終値	2026/05/01 00:00
収益	2025/12/31
年間収益	2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Citius Pharmaceuticals, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。3

アナリスト	機関
Jason Kolbert	D. Boral Capital LLC.
Jason McCarthy	Maxim Group
Michael Okunewitch	Maxim Group

Citius Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.999966 million.

New major risk - Share price stability

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.000001 million.

Insufficient new directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Apr 06, 2026

New major risk - Financial position

Citius Pharmaceuticals, Inc. Provides Nasdaq Listing Compliance Update

Forecast breakeven date pushed back to 2027

New major risk - Share price stability

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.999749 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.999749 million.

New major risk - Financial position

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.001962 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $6.001962 million.

New major risk - Share price stability

Citius Pharmaceuticals, Inc. announced that it has received $1 million in funding

Forecast breakeven date moved forward to 2025

New major risk - Shareholder dilution

Citius Pharmaceuticals, Inc. announced a financing transaction

Consensus EPS estimates fall from profit to US$1.79 loss

Price target decreased by 85% to US$5.67

Consensus EPS estimates fall from profit to US$0.67 loss, revenue upgraded

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.999873 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare & Medicaid Services

New major risk - Shareholder dilution

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 10, 2025

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3.000006 million.

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Forecast breakeven date moved forward to 2025

Price target decreased by 44% to US$54.00

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Nasdaq Hearings Panel Grants Citius Pharmaceuticals' Request to Continue its Listing on The Nasdaq Capital Market to Regain Compliance with the Bid Price Rule on or before December 3, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (Keytruda®) and Lymphir™ in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Price target increased by 22% to US$4.67

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New major risk - Financial position

New minor risk - Profitability

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

New minor risk - Share price stability

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Price target decreased by 21% to US$3.17

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Consensus EPS estimates fall by 24%

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Forecast breakeven date pushed back to 2025

Price target increased by 25% to US$5.00

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

過去基準チェック /06